April 24, 2020 – AdaptVac, a PREVENT-nCoV consortium member, announces signing of agreement with AGC Biologics for manufacture and scale-up of the COVID-19 (SARS-CoV-2) Coronavirus vaccine. This agreement leverages AGC Biologics global manufacture expertise to accelerate the development and GMP manufacture of the SARS-CoV-2 capsid-Virus Like Particle (cVLP) vaccine. This partnership has the potential to advance the initiation of the first clinical trial to the end of 2020.
“The addition of AGC Biologics as partner now completes our consortium of vaccine experts and addresses future large-scale production needs for the COVID-19 vaccine. We are grateful to AGC for providing their world-leading expertise and development support. Their collaboration will ensure vaccine production can happen in the fastest possible time-line.” says Wian de Jongh, AdaptVac’s CEO. “In preparation for positive clinical results, we will now actively pursue partnering with large Biotech/Pharma required to ensure rapid vaccine access for the public”.
“The urgency level to develop and produce a vaccine to combat COVID-19 could not be higher,” says AGC Biologics CEO Patricio Massera. “We are honored to partner with AdaptVac and be part of the consortium team that is working to develop an efficient vaccine. We value collaborative partnerships, and believe working together to fight this pandemic is crucial.”
Source: adaptVAC
